Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ALLR
ALLR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALLR News
Allarity Therapeutics Secures $20 Million Financing to Advance Cancer Treatment
1d ago
NASDAQ.COM
Allarity Secures $20 Million Financing to Extend Cash Runway
4d ago
Newsfilter
Allarity Therapeutics Advances Stenoparib with FDA Fast Track Designation
Dec 31 2025
Globenewswire
Allarity Therapeutics CEO Letter Highlights Progress Toward Stenoparib FDA Approval
Dec 31 2025
Newsfilter
3 Penny Stocks to Keep an Eye On as of August 28, 2025
Aug 28 2025
TipRanks
Tuesday's Major Stock Market Highlights: Morning News Summary!
Aug 26 2025
TipRanks
Crude Oil Prices Fall 2%; US Durable Goods Orders Decrease in July
Aug 26 2025
Benzinga
US Stocks Show Varied Performance; American Woodmark Reports Disappointing Sales
Aug 26 2025
Benzinga
What’s Behind the 95% Surge in Allarity Therapeutics Stock (ALLR) Today?
Aug 26 2025
TipRanks
Stock Market Update: S&P 500 and Nasdaq Futures Drop— Earnings Reports from Palo Alto, XP, and Allarity Under Scrutiny
Aug 18 2025
Benzinga
Stocks to Keep an Eye on This Monday: Palo Alto Networks, Fabrinet, and Two Others
Aug 18 2025
Benzinga
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
Aug 15 2025
Newsfilter
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jul 28 2025
Benzinga
Ascendiant Capital Initiates Coverage On Allarity Therapeutics with Buy Rating, Announces Price Target of $9
Jul 28 2025
Benzinga
Allarity Therapeutics Appoints Jeff Ervin To Succeed Alexander Epshinsky As CFO
Jul 07 2025
NASDAQ.COM
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Jun 27 2025
Newsfilter
Show More News
